Compass Therapeutics Files 8-K on Shareholder Vote
Ticker: CMPX · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1738021
| Field | Detail |
|---|---|
| Company | Compass Therapeutics, Inc. (CMPX) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
Compass Therapeutics held a shareholder vote on June 13th. Details filed today.
AI Summary
Compass Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders on June 13, 2024. The filing details the company's principal executive offices located at 80 Guest Street, Suite 601, Boston, Massachusetts.
Why It Matters
This filing indicates that Compass Therapeutics held a shareholder vote, which could pertain to significant corporate decisions or governance changes that may impact investors.
Risk Assessment
Risk Level: low — This is a routine filing reporting on a shareholder vote, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Compass Therapeutics, Inc. (company) — Registrant
- June 13, 2024 (date) — Date of earliest event reported
- June 17, 2024 (date) — Date of report
- 80 Guest Street, Suite 601, Boston, Massachusetts (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders on June 13, 2024?
The filing does not specify the exact matters voted upon, only that a vote occurred on June 13, 2024.
What is the primary business of Compass Therapeutics, Inc.?
Compass Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code.
Where are Compass Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 80 Guest Street, Suite 601, Boston, Massachusetts.
When was the company incorporated or organized?
The company is incorporated in Delaware.
What is the SEC file number for Compass Therapeutics, Inc.?
The SEC file number is 001-39696.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-06-17 08:32:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CMPX NASDAQ Capit
Filing Documents
- f8k_061724.htm (8-K) — 24KB
- 0001171843-24-003463.txt ( ) — 195KB
- cmpx-20240613.xsd (EX-101.SCH) — 3KB
- cmpx-20240613_lab.xml (EX-101.LAB) — 33KB
- cmpx-20240613_pre.xml (EX-101.PRE) — 22KB
- f8k_061724_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 13, 2024 Compass Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders. The final results for each of the matters submitted to a vote of stockholders at the meeting are set forth below. A more detailed description of each proposal is set forth in the Company's definitive proxy statement on Form DEF 14A, filed with the U.S. Securities and Exchange Commission on April 29, 2024. Proposal No. 1. Election of Directors. The stockholders elected the two Class I nominees for director to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth in the table below: Broker Non- Name For Withheld votes Ellen V. Chiniara, J.D. 76,766,213 23,754,485 17,705,143 Mary Ann Gray, Ph.D. 100,051,792 468,906 17,705,143 Proposal No. 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024, by the votes set forth in the table below: Broker Non- For Against Abstained votes 118,180,952 13,785 31,104 0 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: June 17, 2024 By: /s/ NEIL LERNER Neil Lerner VP of Finance